Disaggregation of Revenues, Geographic Sales and Product Sales

12 Months Ended

Dec. 27, 2024

Disaggregation of Revenues, Geographic Sales and Product Sales

Note 16 — Disaggregation of Revenues, Geographic Sales and Product Sales

In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product line. The following breaks down revenues into the following categories (in thousands):


	Years Ended
	2024		2023		2022
Non-consignment sales	$	293,573	$	301,163	$	264,620
Consignment sales		20,328		21,252		19,771
Total net sales	$	313,901	$	322,415	$	284,391

The Company markets and sells its products in more than 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales in that country exceed 10% of consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):


	Years Ended
	2024		2023		2022
Domestic	$	19,896	$	17,221	$	14,679
Foreign:
China(1)		161,321		185,554		148,167
Japan		41,836		38,472		43,093
Other(2)		90,848		81,168		78,452
Total foreign sales		294,005		305,194		269,712
Total net sales	$	313,901	$	322,415	$	284,391

(1) The China region includes sales into China and Hong Kong.

(2) No other location individually exceeds 10% of the total net sales.

The Company’s principal product, ICLs, are used in refractive surgery. Historically the Company marketed and sold cataract IOLs and related injectors and injector parts. The Company phased out sales of such products in fiscal 2023, and it did not sell any such products in fiscal 2024 and it does not expect such sales in the future. The composition of the Company’s net sales by product line was as follows (in thousands):


	Years Ended
	2024		2023		2022
ICLs	$	312,543	$	319,427	$	269,712
Other product sales
Cataract IOLs		—		1,139		9,638
Other surgical products(1)		1,358		1,849		5,041
Total other product sales		1,358		2,988		14,679
Total net sales	$	313,901	$	322,415	$	284,391

(1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances.

The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, U.S. and foreign export and import duties and tariffs, and political instability.